首页 > 市场调查报告书 > 医疗设备

医学影像诊断手术用器具电子医疗设备核子医学

市场调查报告书

商品编码

1517637

萤光导引手术系统市场 - 类型（SPY 系统、PDE 系统、VS3 铱系统）、手术（开放式、腹腔镜/内视镜）、应用（癌症、心血管）- 全球预测（2024 年 - 2032 年）

Fluorescence Guided Surgery Systems Market - Type (SPY System, PDE System, VS3 Iridium System), Surgery (Open, Laparoscopic/Endoscopic), Application (Cancer, Cardiovascular) - Global Forecast (2024 - 2032)

出版日期: 2024年04月24日 | 出版商:

Global Market Insights Inc. | 英文 108 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于癌症盛行率不断上升以及对更精确手术干预的强烈需求，萤光引导手术系统市场规模预计从 2024 年到 2032 年将以 16.3% 的复合年增长率扩大。根据世界卫生组织的数据，2022 年将通报约 2,000 万新癌症病例，导致约 970 万人死亡。这些系统使外科医生能够即时可视化肿瘤和其他关键结构，以提高肿瘤切除的准确性并最大限度地减少对周围健康组织的损害。这项技术在肿瘤学中特别有益，其中恶性组织的精确切除对于患者的治疗效果至关重要。

对医疗基础设施的投资不断增加，以及医疗保健提供者对先进手术技术优势的认识不断提高，将影响市场的成长。政府和私营部门实体正在大力投资升级医疗设施，并为其配备最先进的手术工具，以改善病患照护。萤光成像技术的不断进步，例如新型萤光染料和显影剂的开发，进一步将萤光引导手术的应用范围从肿瘤学扩展到神经外科、心血管外科和骨科等领域。

该行业分为类型、手术、应用和区域。

根据类型，PDE 系统领域的萤光导引手术系统市场价值预计在 2024 年至 2032 年期间将出现强劲增长，因为它能够增强各种疾病的检测和治疗。 PDE 系统利用萤光染料选择性地积聚在病变组织中，使它们在手术过程中在专门的成像设备下高度可见。这项技术还允许外科医生精确识别肉眼或传统影像方法可能看不到的肿瘤边缘和残留癌细胞。

在手术方面，腹腔镜/内视镜手术领域的萤光导引手术系统产业预计将在2024 年至2032 年实现显着的复合年增长率。缩短恢復时间并减少併发症，从而有利于这种增长。萤光导引系统还透过提供血管、淋巴结和肿瘤等关键结构的即时可视化来提高腹腔镜和内视镜手术的精确度和安全性。

亚太地区萤光导引手术系统产业预计将在 2024 年至 2032 年持续成长。中国、印度和日本不断增加的医疗保健支出和基础设施发展导致大量投资用于升级医疗设施和采用先进的外科技术。癌症和其他慢性疾病发生率的上升也推动了对创新诊断和治疗解决方案的需求，以实现更有效的肿瘤检测。医疗保健技术的不断进步以及医疗保健提供者对萤光引导手术益处的认识不断增强也推动了该区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 慢性病盛行率增加
  - 癌症和心血管疾病靶向手术的增长
  - 越来越注重改善手术效果、减少手术时间
  - 旨在改善外科基础设施的政府倡议
- 产业陷阱与挑战
  - 手术设备及耗材成本高
  - 萤光成像程序的报销范围有限
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
间谍系统
偏微分方程系统
VS3铱系统
其他类型

第 6 章：市场估计与预测：按手术分类，2021 - 2032 年

主要趋势
开放性手术
腹腔镜/内视镜手术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
癌症手术
心血管手术
其他应用

第 8 章：市场估计与预测：按地区，2021 - 2032

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Stryker Corporation
Olympus Corporation
KARL STORZ SE & Co. KG
Medtronic plc
Carl Zeiss Meditec AG
Danaher Corporation (Leica Microsystems)
Hamamatsu Photonics K.K.
Shimadzu Corporation
LI-COR, Inc.
PerkinElmer Inc.
Getinge (Fluoptics)
OnLume Inc.
Irillic Pvt. Ltd.
Curadel, LLC

简介目录

Product Code: 9171

Fluorescence Guided Surgery Systems Market size is expected to expand at 16.3% CAGR from 2024 to 2032 driven by the increasing prevalence of cancer and the strong need for more precise surgical interventions. As per WHO, in 2022, approximately 20 million new cancer cases were reported, resulting in around 9.7 million fatalities. These systems enable surgeons to visualize tumors and other critical structures in real-time for enhancing the accuracy of tumor removal and minimizing damages to surrounding healthy tissues. This technology is particularly beneficial in oncology, where precise excision of malignant tissues is crucial for patient outcomes.

The increasing investments in healthcare infrastructure and the rising awareness among healthcare providers about the benefits of advanced surgical technologies will influence the market growth. Governments and private sector entities are investing heavily in upgrading healthcare facilities and equipping them with state-of-the-art surgical tools to improve patient care. The continuous advancements in fluorescence imaging technology, such as the development of new fluorescent dyes and imaging agents, are further expanding the applications of fluorescence-guided surgery beyond oncology to fields like neurosurgery, cardiovascular surgery, and orthopedics.

The industry is segmented into type, surgery, application and region.

Based on type, the fluorescence guided surgery systems market value from the PDE system segment is slated to witness robust growth rate over 2024-2032 due to its ability to enhance the detection and treatment of various diseases. PDE systems utilize fluorescent dyes that selectively accumulate in diseased tissues, making them highly visible under specialized imaging devices during surgery. This technology also allows surgeons to precisely identify tumor margins and residual cancerous cells that may not be visible to the naked eye or conventional imaging methods.

With respect to surgery, the fluorescence guided surgery systems industry from the laparascopic/endoscopic surgery segment is poised to depict significant CAGR from 2024 to 2032. The growth is favored by the increasing demand for minimally invasive procedures that offer reduced recovery times and fewer complications compared to traditional open surgeries. Fluorescence-guided systems also enhance the precision and safety of laparoscopic and endoscopic surgeries by providing real-time visualization of critical structures, such as blood vessels, lymph nodes, and tumors.

Asia Pacific fluorescence guided surgery systems industry is projected to depict sustained growth from 2024-2032. The increasing healthcare expenditure and infrastructure development across China, India, and Japan, are leading to heavy investments for upgrading medical facilities and adopting advanced surgical technologies. The rising incidence of cancer and other chronic diseases is also driving the need for innovative diagnostic and treatment solutions that enable more effective tumor detection. Rising advancements in healthcare technology and the growing awareness among healthcare providers about the benefits of fluorescence-guided surgery are also driving the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Growth in targeted surgeries for cancer and cardiovascular disorders
  - 3.2.1.3 Growing focus towards improving surgical outcomes and reducing operating time
  - 3.2.1.4 Government initiatives aimed at improving surgical infrastructure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of surgical equipment and consumables
  - 3.2.2.2 Limited reimbursement coverage for fluorescence imaging procedures
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 SPY system
5.3 PDE system
5.4 VS3 iridium system
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Surgery, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Open surgery
6.3 Laparoscopic/endoscopic surgery

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer surgeries
7.3 Cardiovascular surgeries
7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa